A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
for High-Risk Prostate Cancer
6 locations incl. West Los Angeles
Sponsor: VA Office of Research and Development
Sex: Male·Age: 18+
Code: NCT05593497·Phase 2·Recruiting